Decreased expression of β1- and β2-adrenoceptors in human diabetic atrial appendage
© Dinçer et al; licensee BioMed Central Ltd. 2003
Received: 09 April 2003
Accepted: 20 June 2003
Published: 20 June 2003
Using the streptozotocin-induced diabetic rat model, we have recently showed that the expression and function of β1-adrenoreceptor were decreased in the diabetic rat heart. However, the effect of diabetes on expression of β-adrenoreceptors in human cardiac tissue remains undefined. Therefore, the focus of the present study was to investigate the effect of diabetes on mRNA encoding β1- and β2-ARs in human atrial tissues.
Right atrial appendages from five diabetic (mean age 65 ± 4.5; 4 female, 1 male) and five nondiabetic patients (mean age 56.2 ± 2.8; 4 male, 1 female) undergoing coronary artery bypass grafting were collected and assayed using reverse transcriptase-polymerase chain reaction (RT-PCR) for their mRNA content. No patient from these two groups suffered from acute myocardial infarction and/or failure. All diabetic patients received insulin for at least two years and had been diagnosed as diabetics for at least five years.
When compared with levels in nondiabetics, steady state levels of mRNA encoding β1-adrenoreceptor decreased by 69.2 ± 7.6 % in diabetic patients while β2-adrenoreceptor mRNA decreased by 32.2 ± 5.5 % (p < 0.001).
Our findings show a decreased expression of β1- and β2-adrenoreceptors in human diabetic atrial appendage.
During the last two decades, significant efforts have been made by several laboratories for a better understanding of the molecular basis underlying cardiovascular complications in diabetics. As it is well known, these complications are responsible for the increased incidence of morbidity and mortality in this patient group and are brought about by metabolic and biochemical shifts as well as by ultrastructural alterations [1, 2]. A substantial body of literature indicated that β-adrenoreceptors (AR)s are involved in altered cardiac contraction and/or velocity in different types and stages of heart disease. At early stages, the heart compensate by increasing its neurohumoral and neuroendocrine system activity. However, at later stages, excessive amounts of catecholamine stimulation could have harmful effects on the already failing myocardium . Changes in expression and function of β-ARs depend on the type and stage of heart failure and also depend on the region of the heart .
Some of the hallmarks of diabetes induced cardiomyopathy are bradycardia, nonhomogeneity of atrial conduction and prolongation of sinus node recovery times . Our laboratory previously demonstrated that diabetes has altered the responsiveness, function and expression of the β-ARs in the STZ-diabetic rat heart [6–8]. In addition to STZ-diabetic rat model, we also studied the inotropic responses to β-AR stimulation using atrial appendages from diabetic and nondiabetic humans. In those studies we demonstrated that the full agonist potency order was isoprenaline = fenoterol > noradrenaline . However, no data is currently available on the levels of β-ARs in human diabetic atria. Thus, the aim of the present study was to compare the relative levels of β-AR subtypes in diabetic and nondiabetic human atrial appendages.
Protocol for collection, storage and analysis of human tissues was reviewed and approved by the Başkent University School of Medicine Ethics Committee. Age and sex dispersion as well as medical history of subjects were prospectively obtained from 51 diabetic and nondiabetic patients from undergoing coronary bypass operation in cardiovascular department for two month period. However, only 10 atria selected and collected (5 of each group) to analyze mRNA expression. For the purpose of this study, samples for analysis based on the following criteria; they should (i) be angiographically proven coronary artery disease. The point that all patients presented with coronary artery disease is important because it allows for the interpretations that differences between nondiabetic and diabetic tissues most likely reflect the presence of diabetes, not just due to the consequences of ischemia (ii) have not suffered from prior acute myocardial infarction and/or heart failure (iii) the nondiabetic group has no history of cardiac diseases (they were sudden angina pectoris and then needed by-pass operation), and (iv) all diabetic patients have been diagnosed for at least five years and receiving insulin therapy (24 ± 5 U/day) for at least two years. Using these criteria, five diabetic (insulin-treated) samples (age; 65 ± 4.5, sex; 4F/1M, n = 5) and five nondiabetic samples (age, 56.2 ± 2.8; 4M, 1F) were chosen for mRNA analysis. The diabetic group had been treated with insulin (n = 5), calcium antagonists (n = 2), nitrovasodilators (n = 2) and aspirin (n = 5), on the other hand nondiabetic patients had received calcium antagonists (n = 2), ACE inhibitors (n = 2) and aspirin (n = 2). None of the patients received β-AR blocking agents for their medication before the operation. All diabetic patients had normal glucose concentration before the operation. Dolantin, promethazine and atropine were given as premedication and operation was carried out under balanced anaesthesia with fentanyl and isoflurane. Heparin, prednisolone, dopamine, nitroglycerin and anti-arrhythmic were also given to some patients.
Isolation and quantitation of total RNA
Atrial appendages (≈ 100 mg tissues) removed, placed in liquid N2 and then stored at -80°C. Total RNA were extracted using the procedure provided with Quick Prep® total RNA extraction kit (Amersham Pharmacia Biotech, Piscataway, New Jersey) as described before [6, 9]. At the end of the isolation, RNA samples were dissolved in diethylpyrocarbonate (DEPC)-treated water (pH 7.5) and the optical density (OD) values of each sample were determined spectrophotometrically using UV-visible spectrophotometer (UV-1601, Shimadzu, Japan) at wavelength 260 nm (λ260) and 280 nm (λ280). The amount of RNA in each sample was then determined using the formula, [RNA] = ODλ260 X dilution factor X 40 μg/ml. OD values of RNA samples were also determined at λ280 and the ODλ260 / ODλ280 ratio were used as cursory estimations of RNA quality (6). RNA samples were electrophoresed using denaturing (formamide/ formaldehyde) agarose gels to qualitatively assess for any degradation that may have occurred during the isolation.
Preparation of first strand cDNA via reverse transcriptase reactions
RNA samples with distinct 18S and 28S ribosomal RNA bands on denaturing agarose gels were then used as templates for synthesis of first strand cDNAs as described previously (6, 9). Briefly, 1 μl of oligo dT12–18 (Life Technologies-Gibco BRL, Gaithersburg, MD, USA) was added to equivalent amounts of total RNA from control and diabetic human atrial appendages. The mixtures were then placed into a thermocycler (Hybaid, PCR Express, UK) and held at 70°C for 10 min. At the end of this time, the samples were transferred into ice bath for 5 min to permit selective binding of the oligo dT12–18 to the poly-A tail of the mRNA. Thereafter, 1 μl of 10 mM deoxynucleotide triphosphate (dNTP), 2 μl of 0.1 M dithiothreitol (DTT), 4 μl of 5 X 1st strand buffer, 1 μl Superscript II and 1 μl RNasin were added followed by water for a final volume of 20 μl. The tubes were again placed into the thermocycler and heated for 45 min at 42°C for reverse transcription followed by 5 min at 94°C for denaturation. First strand cDNA samples were then cooled to 4°C and stored at -80°C until use.
Amplification of cDNA encoding β-AR subtypes
Primers used in PCR reactions.
Primer sequence 5'-3'
PCR product size (bp)
Annealing Temperature (°C)
Data analysis and statistics
Differences between values of all groups were evaluated by student t test. The experimental data are mean ± standard error of mean (S.E.M) of n experiments. Results were considered significantly different at P < 0.01.
Age and sex dispersion of subjects
For this study only ten of the 51 samples satisfied the selection criteria (nondiabetic group; mean age, 56.2 ± 2.8 and sex 4M/1F, n = 5, diabetic group; mean age, 65 ± 4.5 and sex, 4F/1M, n = 5) and collected for mRNA expression experiment.
Quantitation of total RNA isolated from human hearts
Optical density (OD) values at λ260 and ratios of ODλ260/ODλ280 were used to quantitate as well as to estimate the quality of total RNA isolated from the diabetic and nondiabetic human atria. All samples used for analysis were of similar quality (ODλ260/ODλ280 ratios ~ 1.7) and showed distinct 18 and 28S bands on denaturing agarose gels.
Quantitation of β-AR transcripts
We have previously demonstrated that β1-ARs mediated chronotropic responses decreased by 29%, but β2-ARs mediated responses preserved in 14-week diabetic rat atria . In the same study the inotropic responses to β-AR agonists were also studied on diabetic and nondiabetic human atrial tissues. The full agonist potency order was isoprenaline > or = fenoterol > noradrenaline. We have also previously demonstrated that β1-ARs mRNA decreased to 65.1 % but β2-ARs mRNA expression increased to 72.5 % in 14 week STZ-diabetic rat heart .
In this study we used human atrial appendages obtained from highly selected group of patients. Unfortunately, this lead to a very small final population. Unlike the STZ-induced diabetic rat model, it is very difficult to find out large sample size of patients. Nevertheless, our present result (decreased to 69.2 ± 7.6%) in human atrial appendage related with β1-ARs mRNA expression is very similar if compared with our previous results in the 14-week STZ diabetic rat heart.
As a matter of fact, β2-ARs expression is still indefinite, contrarily to the β1-AR subtype in different model of heart failure. Bristow et al. demonstrated that β1- but not β2-ARs are downregulated by 50% in the human ventricles, not specifically in diabetic heart but during CHF . Decreased expression of β1-ARs and stimulatory protein Gs and increased expression of inhibitory protein Gi have extensively been investigated in different types of human heart failure by many investigators [10–15]. Like the other types of heart failure, high levels of circulating catecholamine levels lead to decreased expression of cardiac β-ARs and to diminished β-ARs mediated inotropic and chronotropic responses in the diabetic heart [16, 17]. The hazardous effects of elevated catecholamine levels are mediated primarily by β1-ARs, contrary to β2-ARs stimulation, which may be adaptive in some cases . Nevertheless, in contrast to other types of heart failure, the diabetes mellitus is a complex metabolic disorder and the elevation of circulating blood glucose level possibly alters the structures of many proteins in the heart. These structural and ultrastructural alterations could lead to transcriptional or posttranslational modifications of these proteins. However, if insulin therapy is applied, the cardiac disturbances could be restored partially or completely in the early stage of diabetic heart even if catecholamine levels are still considerably high [6, 9]. In the early stage, the cardiac disturbances can return to almost normal levels by insulin therapy, unfortunately, in more chronic stages this is mostly irreversible. For this reason, probably the blood glucose variations shift the present disturbances to the irreversible side and/or trigger the initiation of new pathologies in the diabetic heart.
As it is well known, β1- and β2-ARs each couple to Gs. However, a growing body of recent evidence suggests that β2-ARs, but not β1-ARs also couple to the inhibitory protein Gi [14, 15]. Brodde et al. indicated that β2-ARs are more effectively coupled to adenylate cyclase than are β1-ARs in the human right atrium . They also suggested that isoprenaline and adrenaline cause almost same increases in force of contraction via β1- and β2-ARs stimulation because of the more effective coupling of β2 ARs to adenyly cyclase in vitro on isolated human right atrium in spite of the predominance of β1-ARs density . Similarly, we have previously demonstrated that β2-selective agonist fenoterol was more potent than β1-selective agonist noradrenaline on the human right atrium obtained from coronary artery by-pass grafting diabetic and nondiabetic patients .
At the same time, we used PCR reactions that simultaneously amplify cDNAs encoding for β3-AR in different MgCl2 concentrations as well as annealing temperatures. Different set of gene specific primers were used for β3-AR transcripts: sense 839CCTTCCTCTTCTCGTGATGC858 and anti-sense-1492TCTGAACAGAGGCCAGAGGT1473, sense 1659AGTGGTAGTGTCCAGGTGCC1678 and anti-sense 2156AAGCCAGCGCAGAGTAGAAG2137, (Primers were designed based on published sequences in the National Center for Biotechnology Information GenBank database; http://www3.ncbi.nlm.nih.gov/entrez/, accession number NM_000025) and sense AGGTTATCCTGGATCACATG and anti-sense CTGGCTCATGATGGGCGC (Last primers based on the previous report; Gauthier, 1996) . Consequently we could not detect the presence of β3-AR mRNA expression in human atrial appendage from both patient groups. It may depend on very small amount of β3-AR mRNA expression in human atrial appendage.
In our present study we also found that β1/β2 mRNA ratio was 67% in nondiabetic however, 43% in diabetic human atrial appendages (Figure 3). Brodde et al. also demonstrated that atrial and ventricular β1- and β2-ARs density was different in human myocardium [the β1/β2 ratio is about 60/70:40/30 % in the atria ; 70/80:30/20 % in the ventricles] . Furthermore, Rodefeld et al. demonstrated that in human sinoatrial nodes β1-ARs densities were 3 times and β2-ARs densities were 2.5 times higher than right atria. However β1-AR subtypes predominate in sinoatrial node . We can also speculate that β1- and β2-ARs mRNA expression and β1/β2 ratio could be attenuated in sinoatrial node in diabetic patients and it could be one of the reason to decreased chronotropism seen in diabetic patients. Further studies are necessary to reveal the disturbances of sinoatrial β-ARs subtypes in diabetic atria.
Study results are obtained from very small final population. This mainly depends on highly selected group of patient samples. Due to the same reason, age differences between diabetic and non diabetic subgroups look quite different and this may influence the results. Age-associated diminution in myocardial β-ARs has been widely demonstrated. However, Brodde et al. demonstrated that β-AR function with increasing age is not due to alterations in receptor density but involves an impairment of the activity of the catalytic unit of the adenylyl cyclase in human right atrium .
The principal finding of the present study is that in diabetic human atria, β1-ARs mRNA expression is extensively decreased, while β2-ARs mRNA expression is moderately decreased.
List of abbreviations used
polymerase chain reaction
reverse transcription-polymerase chain reaction
congestive heart failure
angiotensin converting enzyme
This work was supported in part by grants from Ankara University Interdisciplinary Biotechnology Department (2002–65), TUBITAK (SBAG-AYD-385) to Ü.D.D. and National Institutes of Health (R01-HL66898) to KRB.
- Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979, 241: 2035-2038. 10.1001/jama.241.19.2035.View ArticlePubMedGoogle Scholar
- Rodrigues B, McNeill JH: The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovas Res. 1992, 26: 913-922.View ArticleGoogle Scholar
- Lefkowitz RJ, Rockman HA, Koch WJ: Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000, 101: 1634-7.View ArticlePubMedGoogle Scholar
- Wang X, Dhalla NS: Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure. Mol Cell Biochem. 2000, 214: 131-55. 10.1023/A:1007131925048.View ArticlePubMedGoogle Scholar
- Fein FS, Aronson RS, Nordin C, Miller-Green B, Sonnenblick EH: Altered myocardial response to ouabain in diabetic rats: mechanics and electro physiology. J Mol Cell Cardiol. 1983, 15: 769-84.View ArticlePubMedGoogle Scholar
- Dinçer ÜD, Bidasee KR, Güner S, Tay A, Özçelikay AT, Altan VM: The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes. 2001, 50: 455-61.View ArticlePubMedGoogle Scholar
- Dinçer ÜD, Özçelikay AT, Yýlmaz ED: The effects of chronic L-name and L-arginine administration on beta-adrenergic responsiveness of STZ-diabetic rat atria. Pharmacol Res. 2000, 41: 565-70. 10.1006/phrs.1999.0623.View ArticlePubMedGoogle Scholar
- Dinçer ÜD, Onay A, Arý N, Özçelikay AT, Altan VM: The effects of diabetes on beta-adrenoceptor mediated responsiveness of human and rat atria. Diabetes Res Clin Pract. 1998, 40: 113-22. 10.1016/S0168-8227(98)00034-5.View ArticlePubMedGoogle Scholar
- Bidasee KR, Dinçer ÜD, Besch HR: Ryanodine receptor dysfunction in hearts of streptozotocin-induced diabetic rat hearts. Mol Pharmacol. 2001, 60: 1-9.Google Scholar
- Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM: Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993, 92: 2737-2745.PubMed CentralView ArticlePubMedGoogle Scholar
- Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986, 74: 1290-302.View ArticlePubMedGoogle Scholar
- Schotten U, Filzmaier K, Borghardt B, Kulka S, Schoendube F, Schumacher C, Hanrath P: Changes of beta-adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease. Am J Physiol Heart Circ Physiol. 2000, 278: H2076-83.PubMedGoogle Scholar
- Freeman K, Lerman I, Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ, Leinwand LA: Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. J Clin Invest. 2001, 107 (8): 967-74.PubMed CentralView ArticlePubMedGoogle Scholar
- Liggett SB: Beta-adrenergic receptors in the failing heart: the good, the bad, and the unknown. J Clin Invest. 2001, 107: 947-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Lefkowitz RJ, Rockman HA, Koch WJ: Catecholamines, cardiac beta-adrenergic receptors, and heart failure. Circulation. 2000, 101: 1634-7.View ArticlePubMedGoogle Scholar
- Paulson DJ, Shetlar D, Light KE: Catecholamine levels in the heart, serum and adrenals of experimental diabetic rats. Fed Proc. 1980, 39: 637.Google Scholar
- Christensen NJ: Plasma norepinephrine and epinephrine in untreated diabetics during fasting and after insulin administration. Diabetes. 1974, 23: 1-8.View ArticlePubMedGoogle Scholar
- Brodde OE, O'Hara N, Zerkowski HR, Rohm N: Human cardiac beta-adrenoceptors: both beta 1- and beta 2-adrenoceptors are functionally coupled to the adenylate cyclase in right atrium. J Cardiovasc Pharmacol. 1984, 6: 1184-91.View ArticlePubMedGoogle Scholar
- Kaumann AJ: Four β-AR subtypes in the mammalian heart. Trends Pharmacol Sci. 1997, 18: 70-76. 10.1016/S0165-6147(96)01033-4.View ArticlePubMedGoogle Scholar
- Brodde OE, Michel MC: Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999, 51: 651-90.PubMedGoogle Scholar
- Rodefeld MD, Beau SL, Schuessler RB, Boineau JP, Saffitz JE: Beta adrenergic and muscarinic cholinergic receptor densities in the human sinoatrial node: Identification of a high beta 2-adrenergic receptor density. J Cardiovasc Electrophysiol. 1996, 7: 1039-1049.View ArticlePubMedGoogle Scholar
- Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H: Functional beta3-adrenoceptor in the human heart. J Clin Invest. 1996, 98: 556-62.PubMed CentralView ArticlePubMedGoogle Scholar
- Brodde OE, Zerkowski HR, Schranz D, Broede-Sitz A, Michel-Reher M, Schafer-Beisenbusch E, Piotrowski JA, Oelert H: Age-dependent changes in the β-Adrenoceptor-G Protein(s)-Adenylyl Cyclase system in human right atrium. J Cardiovasc Pharmacol. 1995, 26: 20-6.View ArticlePubMedGoogle Scholar
- Brian D Lowes, Wayne Minobe, William T Abraham, Mona N Rizeq, Teresa J Bohlmeyer, Robert A Quaife, Robert L Roden, Darin L Dutcher, Alastair D Robertson, Norbert F Voelkel, David B Badesch, Bertron M Groves, Edward M Gilbert, Michael R Bristow: Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in. J Clin Invest. 1997, 100: 2315-24.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.